血栓症和止血生物標記市場規模、佔有率和成長分析：按生物標記類型、產品類型、應用、技術、最終用戶、樣本類型和地區分類－2026-2033年產業預測

2024 年全球血栓症和止血生物標記市場價值為 52 億美元，預計到 2033 年將從 2025 年的 56 億美元成長到 100.5 億美元，預測期（2026-2033 年）的複合年成長率為 7.6%。

全球血栓症和止血生物標記市場正崛起為診斷和個人化醫療的重要組成部分，透過測量分子、細胞和功能參數，深入了解凝血障礙和出血風險。心血管疾病和惡性腫瘤相關血栓症的日益普遍推動了該市場的成長，進而刺激了對D-二聚體和高級凝血檢測等高靈敏度檢測的需求。該市場正從基礎血液凝固檢驗發展到先進的多重免疫檢測和基因組分析，從而提高診斷的速度和準確性。將生物標記檢測整合到臨床工作流程中，可將檢測結果與風險評估和治療策略連結起來，從而改善決策，最佳化醫院運作並降低成本。數位分析技術的創新以及製造商與電子健康記錄(EHR) 系統之間的合作將進一步增強數據驅動的臨床決策。

全球血栓症和止血生物標記市場按生物標記類型、產品類型、應用、技術、最終用戶、檢體類型和地區進行細分。依生物標記類型分類，市場可分為D-二聚體、纖維蛋白原、血小板功能生物標記、凝血因子生物標記、凝血酶生成生物標記和其他生物標記。依產品類型分類，市場可分為試劑和試劑盒、儀器和分析儀、耗材以及軟體和服務。依應用分類，市場可分為深層靜脈栓塞症（DVT）、肺動脈栓塞、彌散性血管內凝血（DIC）、心血管疾病、血友病及出血性疾病等疾病。依技術分類，市場可分為免疫檢測、分子診斷、比色法、流式細胞技術等。按終端用戶分類，市場可分為醫院、診斷檢查室、學術和研究機構以及專科診所等。依檢體類型分類，市場可分為血漿、全血、血清等。依地區分類，市場可分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球血栓症和止血生物標記市場的成長要素

隨著心血管疾病盛行率的上升，及時進行風險分層至關重要，這導致對準確識別血栓症和止血生物標記的需求日益成長。臨床上對透過早期診斷和介入實現最佳治療效果的日益關注，正在推動檢查室和醫療機構的創新，並促進新檢測方法的開發。隨著醫療機構將這些先進的生物標記檢測納入其診斷系統，預計製造商將擴大生產規模，並加強相關試劑和設備的研發。對個人化照護和血栓事件預防的持續重視，預計將進一步刺激全球診斷產品市場的發展。

全球血栓症和止血生物標記市場面臨的限制因素

全球血栓症和止血生物標記市場面臨許多挑戰，主要源自於複雜的監管環境和分散的健保報銷體系。這些複雜性延長了產品核准時間，阻礙了市場准入。製造商被迫投入大量資源以滿足各地不同的監管要求，這往往導致創新資金被挪用，從而限制了產品的商業性擴充性。此外，新生物標記檢測的報銷和保險覆蓋範圍存在不確定性，常常使支付方難以迅速認可其診斷價值，並降低了臨床檢查室採用這些創新技術的意願。這些因素共同構成了商業化壁壘，阻礙了市場的快速成長。

血栓症和止血生物標記的全球市場趨勢

全球血栓症和止血生物標記市場正經歷著向即時診斷（POC）檢測的顯著轉變，這主要受臨床環境中對快速便捷的檢測結果需求不斷成長的推動。隨著臨床醫生尋求加速治療決策並縮短住院時間，快速檢測解決方案的普及程度也不斷提高。供應商正致力於創新檢體處理和儀器設計，以簡化工作流程並滿足門診和急診室的需求。這種轉變不僅支持了更廣泛的篩檢工作，也促進了診斷、檢測和即時診斷服務業之間的合作，從而為新的市場機會和改善患者預後鋪平了道路。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球血栓症和止血生物標記市場規模：按生物標記類型分類

• D-二聚體
• 纖維蛋白原
• 血小板功能生物標記
• 凝血因子生物標記物
• 凝血酶生成生物標記
• 其他

全球血栓症和止血生物標記市場規模：按產品類型分類

• 試劑和試劑盒
• 儀器/分析儀
• 消耗品
• 軟體服務

全球血栓症和止血生物標記市場規模：按應用分類

• 深層靜脈栓塞症（DVT）
• 肺動脈栓塞
• 瀰漫性血管內凝血（DIC）
• 心血管疾病
• 血友病及出血性疾病
• 其他

全球血栓症和止血生物標記市場規模：按技術分類

• 免疫檢測
• 分子診斷
• 顯色測定法
• 流式細胞技術
• 其他

全球血栓症和止血生物標記市場規模：按最終用戶分類

• 醫院
• 診斷檢查室
• 學術研究機構
• 專科診所

全球血栓症和止血生物標記市場規模：按樣本類型分類

• 電漿
• 全血
• 血清

全球血栓症和止血生物標記市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Siemens Healthineers
• Roche Diagnostics
• Abbott Laboratories
• Danaher Corporation
• Sysmex Corporation
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• Werfen
• Diagnostica Stago
• Instrumentation Laboratory
• Sekisui Diagnostics
• QuidelOrtho
• Fujirebio
• DiaSys Diagnostic Systems
• Trinity Biotech
• Helena Laboratories
• Hyphen BioMed
• Haemonetics
• Aptamer Group
• Creative Diagnostics

結論與建議

Global Thrombosis And Hemostasis Biomarkers Market size was valued at USD 5.20 Billion in 2024 and is poised to grow from USD 5.60 Billion in 2025 to USD 10.05 Billion by 2033, growing at a CAGR of 7.6% during the forecast period (2026-2033).

The global thrombosis and hemostasis biomarkers market is emerging as a vital component in diagnostics and personalized medicine, providing insights into clotting disorders and bleeding risks through the measurement of molecular, cellular, and functional parameters. Its growth is propelled by the rising prevalence of cardiovascular diseases and malignancy-associated thrombosis, spurring demand for sensitive assays like D-dimer and advanced coagulation panels. The market has evolved from basic coagulation tests to sophisticated multiplex immunoassays and genomic profiling, enhancing diagnostic speed and accuracy. Integrating biomarker testing into clinical workflows improves decision-making by linking assay results to risk assessments and treatment strategies, thereby optimizing hospital operations and reducing costs. Innovations in digital analytics and collaborations between manufacturers and EHR systems will further enhance data-driven clinical decision-making.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Thrombosis And Hemostasis Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Thrombosis And Hemostasis Biomarkers Market Segments Analysis

Global thrombosis and hemostasis biomarkers market is segmented by biomarker type, product type, application, technology, end user, sample type and region. Based on biomarker type, the market is segmented into D-Dimer, fibrinogen, platelet function biomarkers, coagulation factor biomarkers, thrombin generation biomarkers and others. Based on product type, the market is segmented into reagents & kits, instruments & analyzers, consumables and software & services. Based on application, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism, disseminated intravascular coagulation (DIC), cardiovascular disorders, hemophilia & bleeding disorders and others. Based on technology, the market is segmented into immunoassays, molecular diagnostics, chromogenic assays, flow cytometry and others. Based on end user, the market is segmented into hospitals, diagnostic laboratories, academic & research institutes and specialty clinics. Based on sample type, the market is segmented into blood plasma, whole blood and serum. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Thrombosis And Hemostasis Biomarkers Market

The rising prevalence of cardiovascular diseases has heightened the demand for accurate identification of thrombosis and hemostasis biomarkers, as timely risk stratification is crucial. This growing clinical interest in achieving optimal health outcomes through early diagnosis and intervention has spurred laboratories and healthcare facilities to innovate and develop new assays. As healthcare providers adopt these advanced biomarker tests into their diagnostic frameworks, manufacturers are likely to ramp up production and enhance the development of associated reagents and instrumentation. Continued emphasis on personalized patient management and the prevention of thrombotic events is set to further energize the global market for diagnostic products.

Restraints in the Global Thrombosis And Hemostasis Biomarkers Market

The Global Thrombosis and Hemostasis Biomarkers market faces significant challenges stemming from intricate regulatory landscapes and fragmented reimbursement systems. These complexities prolong product approval timelines and hinder market access. Manufacturers are compelled to invest substantial resources in meeting diverse regional requirements, which often diverts funds from innovation and restricts the commercial scalability of their products. Additionally, uncertainties surrounding reimbursement and coverage for new biomarker tests diminish the motivation for clinical laboratories to adopt these innovations, as payers frequently fail to recognize their diagnostic value promptly. Together, these factors create barriers to commercialization and impede swift market growth.

Market Trends of the Global Thrombosis And Hemostasis Biomarkers Market

The Global Thrombosis and Hemostasis Biomarkers market is witnessing a significant trend towards Point-of-Care (POC) diagnostic testing, driven by an increasing demand for timely and accessible results in clinical settings. As clinicians seek to expedite therapeutic decision-making and reduce hospital stays, the availability of rapid testing solutions is expanding. Vendors are innovating in sample handling and instrument design to cater to outpatient clinics and emergency departments, enhancing workflow efficiencies. This shift not only supports broader screening initiatives but also fosters collaboration among diagnostic, laboratory, and POC service industries, paving the way for new market opportunities and improved patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Thrombosis And Hemostasis Biomarkers Market Size by Biomarker Type & CAGR (2026-2033)

• Market Overview
• D-Dimer
• Fibrinogen
• Platelet Function Biomarkers
• Coagulation Factor Biomarkers
• Thrombin Generation Biomarkers
• Others

Global Thrombosis And Hemostasis Biomarkers Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Reagents & Kits
• Instruments & Analyzers
• Consumables
• Software & Services

Global Thrombosis And Hemostasis Biomarkers Market Size by Application & CAGR (2026-2033)

• Market Overview
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism
• Disseminated Intravascular Coagulation (DIC)
• Cardiovascular Disorders
• Hemophilia & Bleeding Disorders
• Others

Global Thrombosis And Hemostasis Biomarkers Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Immunoassays
• Molecular Diagnostics
• Chromogenic Assays
• Flow Cytometry
• Others

Global Thrombosis And Hemostasis Biomarkers Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Academic & Research Institutes
• Specialty Clinics

Global Thrombosis And Hemostasis Biomarkers Market Size by Sample Type & CAGR (2026-2033)

• Market Overview
• Blood Plasma
• Whole Blood
• Serum

Global Thrombosis And Hemostasis Biomarkers Market Size & CAGR (2026-2033)

• North America (Biomarker Type, Product Type, Application, Technology, End User, Sample Type)
  • US
  • Canada
• Europe (Biomarker Type, Product Type, Application, Technology, End User, Sample Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker Type, Product Type, Application, Technology, End User, Sample Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker Type, Product Type, Application, Technology, End User, Sample Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker Type, Product Type, Application, Technology, End User, Sample Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Siemens Healthineers
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Werfen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diagnostica Stago
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Instrumentation Laboratory
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sekisui Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QuidelOrtho
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSys Diagnostic Systems
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Trinity Biotech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Helena Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hyphen BioMed
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haemonetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aptamer Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations